Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086748 | 1.00 | P2RX3 (0.83) | P2RX3P2RX2 | |
| SCHEMBL1494179 | 0.91 | P2RX3 (0.69) | P2RX3P2RX2 | |
| SCHEMBL3087024 | 0.91 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL3098235 | 0.89 | P2RX3 (0.67) | P2RX3P2RX2 | |
| SCHEMBL3091239 | 0.89 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL4410783 | 0.89 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL3101474 | 0.89 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL14605911 | 0.88 | P2RX3 (0.68) | P2RX3P2RX2 | |
| SCHEMBL3090903 | 0.88 | P2RX3 (0.83) | P2RX3P2RX2 | |
| SCHEMBL3085036 | 0.88 | P2RX3 (0.77) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114703227-A | MCF-7 cell line-based constructed RAR alpha effect in-vitro screening method | 中国科学院生态环境研究中心 | 2022-07-05 | — | — | CN | claimed |
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260070915-A1 | SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250218638-A1 | COMMON MODE NOISE FILTER | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-07-03 | — | — | US | disclosed |
| CN-119676861-A | Communication method, device and storage medium | 展讯半导体(南京)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119545529-A | Communication method, device and storage medium | 展讯半导体(南京)有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025031316-A1 | COMMUNICATION METHOD AND APPARATUS, AND STORAGE MEDIUM | 展讯半导体(南京)有限公司 | 2025-02-13 | — | — | WO | disclosed |
| CN-119259231-A | Crushing control system and method of medical waste treatment equipment | 北京大白鲨环保科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118830038-A | Common mode noise filter | 松下知识产权经营株式会社 | 2024-10-22 | — | — | CN | disclosed |
| CN-118741745-A | Communication method and related device | 展讯半导体(南京)有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| US-11921425-B2 | Hard mask-forming composition and method for manufacturing electronic component | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| WO-2023190594-A1 | COMMON MODE NOISE FILTER | パナソニックＩＰマネジメント株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230221643-A1 | HARD MASK-FORMING COMPOSITION AND METHOD FOR MANUFACTURING ELECTRONIC COMPONENT | TOKYO OHKA KOGYO CO LTD (JP) | 2023-07-13 | — | — | US | disclosed |
| US-11650503-B2 | Hard mask-forming composition and method for manufacturing electronic component | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114703227-A | MCF-7 cell line-based constructed RAR alpha effect in-vitro screening method | 中国科学院生态环境研究中心 | 2022-07-05 | — | — | CN | disclosed |
| CN-114703227-A | MCF-7 cell line-based constructed RAR alpha effect in-vitro screening method | 中国科学院生态环境研究中心 | 2022-07-05 | — | — | CN | disclosed |
| US-11331931-B2 | Liquid droplet discharge apparatus | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | P2RX3 4435/4885P2RX2 4446/4885 |
| US-20260070915-A1 | SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS | CDK4, CDK2, CCNC | P2RX3 3938/4885P2RX2 3991/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | P2RX3 2467/4885P2RX2 2724/4885 |
| US-20240084305-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | MKI67, MYC, CCNK | P2RX3 4562/4885P2RX2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.